Myomo (NYSE:MYO) announced today that new research demonstrated benefits with its MyoPro myolectric orthosis.
Results from the study, funded by the U.S. Army Medical Research Acquisition Activity, and supported by the Office of Secretary of Defense for Health Affairs, were published in the peer-reviewed journal Frontiers in Neurology. Data showed “statistically significant improvements” in a number of motor function measurements.
The study observed 13 individuals with chronic moderate-to-severe arm weakness from stroke or traumatic brain injury, with outcomes collected through in-therapy sessions and at-home use, according to a news release. Dr. Svetlana Pundik, the lead investigator and grant recipient, along with colleagues at the Louis Stokes Cleveland Veterans Administration Medical Center, conducted the study.
Authors stated that gains were seen at week three, increased further during the in-clinic phase and were maintained during the at-home phase, with statistically significant changes in Modified Ashworth Scale, Range of Motion, and Chedoke Arm and Hand Activity Inventory all seen during the in-clinic phase.
Users demonstrated satisfaction with the device throughout the study participation, as recorded by the Orthotic and Prosthetic User’s Survey, Boston-based Myomo said.
“We are encouraged by the continually increasing body of evidence that demonstrates that the use of MyoPro results in clinically significant gains in a relatively short duration of in-person treatment. We look forward to expanding on these results which may lead to innovations in treatment for patients who suffer from chronic upper extremity weakness,” Myomo CMO Dr. Harry Kovelman said in the release. “This data supports why the payer community both in the U.S. and Germany continue to expand its reimbursement coverage for patients. We thank the clinicians and patients involved in this study.”